• René Andrade-Machado, Vanessa Benjumea-Cuartas, and Esteban Jaramillo-Jimenez.
• Epilepsy Section, National Neurology and Neurosurgery Institute, Havana, Cuba. reneandrade1970@yahoo.es
• Clin Neuropharmacol. 2012 May 1; 35 (3): 148-9.

IntroductionLennox Gastaut syndrome (LGS) is an epileptic encephalopathy characterized by tonic, atonic, and atypical absence seizures usually refractory to pharmacological treatment. Patients generally continue with seizures despite treatment with the commercially available antiepileptic drugs (AEDs). Lacosamide (LCM) is a new AED recently approved for treatment of partial onset seizures with or without secondary generalization. Lacosamide has a novel mechanism of action that seems to be different in relation to other conventional AEDs.ObjectiveTo report LCM-caused worsening of tonic seizures and electroencephalographic pattern in a patient with Lennox-Gastaut syndrome.Case ReportWe report the evolution of a patient with LGS resistant to several AEDs with a cryptogenic hepatopathy in whom LCM caused worsening of tonic seizures and electroencephalographic pattern. Once LCM was discontinued, the patient returned to his clinical and electrical baseline.ConclusionLennox Gastaut syndrome may exacerbate tonic seizures and electrical pattern of patients with LGS.

16 keywords...

hide…